IL13 and idiopathic pulmonary fibrosis: In these studies, stable IPF fibroblasts (line S117A) were injected into C.B-17SCID/bg mice and beginning at day 35 after fibroblast injection, groups of 5 mice received one of the following every other day until day 63 after fibroblast injection: PBS (intranasally), IL13-PE (500 ng/dose intranasally), compound vehicle (100 μl orally), AXP1741 (10 mg/kg orally) and AXP2132 (10 mg/kg orally).